Pharmaceuticals News & Press Release Distribution

First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection

YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) inChina has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China. Nivolumab is a mo...

2023-10-30 14:51 1683

Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

* Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressure, liver enzyme, triglyceride, low-density lipoprote...

2023-10-30 08:00 3350

Samyang Holdings Presents Clinical Cases of 'Lafullen® and Croquis®' at KOAT Academic Conference

* Presentation of "Lafullen®" and "Croquis®" Procedures and Clinical Cases... Confirming Product Excellence and Safety * Biodegradable Polymer Filler "Lafullen®" Maintains Natural Volume for 2 Years * "Croquis®" Lifting Threads with Samyang' expertise in Global Biodegradable Suture Threa...

2023-10-30 08:00 1501

Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy

- Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

2023-10-27 21:07 2913

Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy

Henlius Announces NMPA Approvals of Two ADC Candidates for IND

SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the investigational new drug (IND) applications of HLX42 for Injection, a novel EGFR-targeting antibody-drug conjugate (ADC) as well as HLX43, a novel PD-L1-targeting ADC, have been approved by the Na...

2023-10-27 20:16 2864

Peijia Medical Presents Early Clinical Findings of GeminiOne® TEER Device at TCT 2023

SUZHOU, China, Oct. 27, 2023 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the device at ...

2023-10-27 20:00 1315

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerc...

2023-10-27 19:47 2246

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerci...

2023-10-27 19:13 5574

NX Ireland Acquires GDP Certification for Company-owned Warehouse

TOKYO, Oct. 27, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has received Good Distribution Practice (GDP) certification from the Irish Exporters Association (IEA), effectiveSeptember 21, for the temporary storage a...

2023-10-27 14:00 1683

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration Bureau of...

2023-10-27 13:45 1749

Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls

SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will make a late-breaking poster present...

2023-10-27 08:22 1849

Noted National TCM Master Inaugurates New Infinitus Research and Technology Laboratory

GUANGZHOU, China, Oct. 27, 2023 /PRNewswire/ – The unveiling ceremony for the joint laboratory, a collaboration between Infinitus and theShandong University of Traditional Chinese Medicine dedicated toXuezhuo-turbid blood research, took place at Infinitus Plaza. The event drew attention from over...

2023-10-27 08:00 1645

Noted National TCM Master Inaugurates New Infinitus Research and Technology Laboratory

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

* Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services forHope Medicine's first-in-class monoclonal antibody drug, HMI-115. * The first-in-class mAb will benefit endometriosis and androgenetic alopecia patients. SHANGHAI, Oct. 26, 20...

2023-10-26 22:49 1204

Clarity and PSI kick off SAR-bisPSMA Phase III

SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...

2023-10-26 21:00 1154

YS Biopharma Announces Receipt of Nasdaq Notice

GAITHERSBURG, Md., Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-10-26 20:30 3114

HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, due to the sustained growth of major products. * 'HL161ANS', HanAll's second anti-FcRn antibody, demonstrated best-in-class potential through the initial outcome of Phase 1 study. * 'HL192', a Nu...

2023-10-26 19:00 1343

Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China

LAUSANNE, Switzerland, Oct. 26, 2023 /PRNewswire/ -- Fapon, a leading life sciences company, entered into a strategic cooperation agreement with two Swiss biotech companies LASCCO SA and Abionic SA, that granted Fapon an exclusive license to utilize the pancreatic stone protein (PSP) biomarker fo...

2023-10-26 18:33 1637

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the tre...

2023-10-26 18:18 1885

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

World Psoriasis Day 2023: Access for All

STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- Every year on World Psoriasis Day, October 29th, the international psoriatic disease community unites to raise awareness and fight for progress. The theme of 2023, "Access for All," underscores the vital need for Universal Health Coverage (UHC) to ensure t...

2023-10-26 16:00 1593

World Psoriasis Day 2023: Access for All

Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC originating from Chinese biotech, achieves remarkable success in overcoming the therapeutic impasse in HR+/HER2- metastatic breast cancer

CHENGDU, China, Oct. 26, 2023 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) convened its annual meeting inMadrid, Spain, from October 20th to 24th, 2023. As the preeminent academic gathering in the field ofoncology, it brought together global experts in oncology to share the la...

2023-10-26 12:58 1702